See the DrugPatentWatch profile for onivyde
Information regarding free trials for Onivyde is not readily available in the provided context.
What is Onivyde?
Onivyde is a chemotherapy drug used to treat pancreatic cancer [1]. Specifically, it is indicated for use in combination with other medications to treat patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [1].
How does Onivyde work?
Onivyde's active ingredient is irinotecan hydrochloride. It is a topoisomerase I inhibitor, meaning it interferes with a specific enzyme that cancer cells need to divide and multiply [1]. This action ultimately leads to the death of cancer cells.
Who makes Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals, Inc. [1].
When does the Onivyde patent expire?
Details on the specific patent expiry dates for Onivyde are not provided. Drug patent information can be complex and is often tracked by specialized databases.
Are there alternatives to Onivyde for pancreatic cancer?
For patients with metastatic pancreatic adenocarcinoma whose disease has progressed after gemcitabine-based therapy, Onivyde is an option in combination with other drugs. Other treatment approaches for pancreatic cancer may involve different chemotherapy regimens, targeted therapies, immunotherapy, or surgical options, depending on the stage and characteristics of the cancer. Patients should discuss all available treatment options with their oncologist.